Fighting Alzheimer’s – Science Breakthrough
Promising pharmaceutical news was just released regarding a disease that plagues an estimated 6.5 million people across the United States. Alzheimer’s disease will affect around 1 in 9 people older than 65, being the seventh-leading cause of death in the United States. Now, the future is brighter, with Japanese drugmaker (Eye – Say) Eisai just announcing positive results to slow symptoms of Alzheimer’s from a new experimental drug.
Eisai claims the drug, called (Lekane – Mab) lecanemab, has slowed cognitive decline by 27% after 18 months during a phase 3 clinical trial. A little under 1800 patients participated in the randomized controlled trial, where they were either offered the drug or a placebo. Cognitive decline was then measured through a clinical dementia scale, and the observations between the control and test group depicted a slowing of cognitive decline by over a quarter. Experts have quoted the small but noteworthy results as “a first step in the direction of making a significant impact on the disease.” Eisai will plan to publish their findings to the FDA in March and may be the first aid to slow the progression of this terrible global disease.
Want to learn how to invest? Download the Invstr app, where you can play Fantasy Finance and manage a virtual investment portfolio, or open a brokerage account and invest for real. Take our interactive investing course on Invstr Academy and become a better investor today!
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.